General Information of Drug (ID: DR3495)
Drug Name
TAK-491
Prodrug Info TAK-491 is the prodrug of Azilsartan
Synonyms TAK 491
Indication Hypertension [ICD11: BA00-BA04] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 568.5 Topological Polar Surface Area 140
Heavy Atom Count 42 Rotatable Bond Count 10
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 10
Cross-matching ID
PubChem CID
135409642
ChEBI ID
CHEBI:68845
CAS Number
863031-21-4
TTD Drug ID
D0A2RA
Formula
C30H24N4O8
Canonical SMILES
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C
InChI
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
InChIKey
QJFSABGVXDWMIW-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Azilsartan DM016621
135415867
Unclear - Unclear 1 [3]
Azilsartan M-I DM016451
101102054
Reduction - Decarboxylation 2 [3]
Azilsartan M-II DM016648
135742018
Oxidation - O-dealkylation 2 [3]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR011372 TAK-491 Azilsartan Unclear - Unclear ES [3]
MR011373 Azilsartan TAK-491 Metabolite M1 Reduction - Decarboxylation CYP2C8 ... [3]
MR011374 Azilsartan TAK-491 Metabolite M2 Oxidation - O-dealkylation CYP2C9 [3]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2B6 (CYP2B6) DME0020 Homo sapiens
CP2B6_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C8 (CYP2C8) DME0018 Homo sapiens
CP2C8_HUMAN
1.14.14.1
[2]
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[2]
References
1 ClinicalTrials.gov (NCT02480764) TAK-491 (Azilsartan Medoxomil) Compared to Valsartan in Chinese Participants With Hypertension.
2 DrugBank(Pharmacology-Metabolism):TAK-491
3 Development, validation and application of the liquid chromatography tandem mass spectrometry method for simultaneous quantification of azilsartan medoxomil (TAK-491), azilsartan (TAK-536), and its 2 metabolites in human plasma

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.